OBI Pharma, Inc. (TPEX: 4174)
Health Care · Biotechnology · TW
NT$53.70
+27.86% today · +0.6% 1Y
OBI Pharma, Inc. (TPEX: 4174) operates in the Biotechnology industry within the Health Care sector. The company is valued at $220.98M and employs 260 people.
Over the last twelve months the share price has gained 0.6%, trading between 24.30 and 66.80.
Tweenvest scores OBI Pharma, Inc. across four factors: quality 36/100, value 47/100, growth 0/100. Its strongest factor is value.
4174 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $220.98M
- Revenue (TTM)
- $1.64M
- P/E
- —
- EPS
- -11.60
- Dividend yield
- —
- Beta (5Y)
- 0.07
- 52-week high
- NT$66.80
- 52-week low
- NT$24.30
- Avg volume (3M)
- —
- Shares outstanding
- 131.58M
- Employees
- 260
- Next earnings
- —
About OBI Pharma, Inc.
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
- ISIN
- TW0004174008
- Founded
- 2002
- Listed since
- Dec 12, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.NYSEAM: PLX | $223.99M | $2.78 | -0.18% |
| ToolGen IncorporatedKOSDAQ: A199800 | $223.81M | ₩33,450.00 | -3.18% |
| Akebia Therapeutics, Inc.NasdaqCM: AKBA | $221.99M | $0.80 | -0.29% |
| Sionna Therapeutics, Inc.NasdaqGM: SION | $221.54M | $4.74 | -3.37% |
| ADC Therapeutics SANYSE: ADCT | $220.87M | $1.85 | +6.65% |
| HansBiomed CorporationKOSDAQ: A042520 | $219.06M | ₩20,650.00 | -2.82% |
| Panacea Biotec LimitedNSEI: PANACEABIO | $218.50M | Rs345.25 | -3.84% |
| Transgene SAENXTPA: TNG | $214.67M | €0.70 | -0.57% |
Figures last refreshed Oct 11, 2026.